MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET 2022-2028

 

TABLE OF CONTENTS

1.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET – SUMMARY

2.     INDUSTRY OUTLOOK

2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET

2.2. KEY INSIGHTS

2.2.1.    DEVELOPMENT OF NEW PURIFICATION METHODS

2.2.2.    INCREASING PREFERENCE FOR PERSONALIZED MEDICINES

2.3. PORTER’S FIVE FORCES ANALYSIS

2.3.1.    THREAT OF NEW ENTRANTS

2.3.2.    THREAT OF SUBSTITUTES

2.3.3.    BARGAINING POWER OF BUYERS

2.3.4.    BARGAINING POWER OF SUPPLIERS

2.3.5.    THREAT OF COMPETITIVE RIVALRY

2.4. MARKET ATTRACTIVENESS INDEX

2.5. VENDOR SCORECARD

2.6. KEY MARKET STRATEGIES

2.6.1.    PRODUCT LAUNCHES & DEVELOPMENTS

2.6.2.    PARTNERSHIPS & AGREEMENTS

2.7. MARKET DRIVERS

2.7.1.    GROWTH IN THE GERIATRIC POPULATION

2.7.2.    PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS

2.7.3.    INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES

2.8. MARKET CHALLENGES

2.8.1.    HIGH COST OF THERAPY

2.8.2.    HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN

2.9. MARKET OPPORTUNITIES

2.9.1.    INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS

2.9.2.    GROWING CLINICAL TRIALS

3.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE

3.1. IGG

3.2. IGA

3.3. IGM

3.4. IGE

3.5. IGD

4.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE

4.1. INTRAVENOUS

4.2. SUBCUTANEOUS

4.3. INTRAMUSCULAR

5.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION

5.1. HYPOGAMMA GLOBULINEMIA

5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY

5.3. PRIMARY IMMUNODEFICIENCY DISEASES

5.4. MYASTHENIA GRAVIS

5.5. MULTIFOCAL MOTOR NEUROPATHY

5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)

5.7. INFLAMMATORY MYOPATHIES

5.8. SPECIFIC ANTIBODY DEFICIENCY

5.9. GUILLAIN-BARRE SYNDROME

5.10.               OTHER APPLICATIONS

6.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER

6.1. HOSPITALS & CLINICS

6.2. HOMECARE

7.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL

7.1. HOSPITAL PHARMACY

7.2. SPECIALTY PHARMACY

7.3. OTHER SALES CHANNELS

8.     MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK

8.1. UNITED ARAB EMIRATES

8.2. SAUDI ARABIA

8.3. TURKEY

8.4. SOUTH AFRICA

8.5. REST OF MIDDLE EAST & AFRICA

9.     COMPETITIVE LANDSCAPE

9.1. BIOTEST AG

9.2. CHINA BIOLOGIC PRODUCTS INC

9.3. GRIFOLS SA

9.4. LFB GROUP

9.5. CSL BEHRING

9.6. KEDRION BIOPHARMA

9.7. OCTAPHARMA AG

9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.9. BIO PRODUCTS LABORATORY

9.10.               SHANGHAI RAAS BLOOD PRODUCTS CO LTD

9.11.               PFIZER INC

9.12.               SANQUIN PLASMA PRODUCTS BV

9.13.               ADMA BIOLOGICS

9.14.               SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

9.15.               KAMADA LTD

10. RESEARCH METHODOLOGY & SCOPE

10.1.               RESEARCH SCOPE & DELIVERABLES

10.2.               SOURCES OF DATA

10.3.               RESEARCH METHODOLOGY

 

TABLE LIST

TABLE 1: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

TABLE 2: VENDOR SCORECARD

TABLE 3: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)

TABLE 4: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)

TABLE 5: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)

TABLE 6: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)

TABLE 7: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)

TABLE 8: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)

 

 

FIGURE LIST

FIGURE 1: MARKET ATTRACTIVENESS INDEX

FIGURE 2: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)

FIGURE 3: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)

FIGURE 4: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)

FIGURE 5: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)

FIGURE 6: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)

FIGURE 7: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)

FIGURE 8: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)

FIGURE 9: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)

FIGURE 10: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)

FIGURE 11: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)

FIGURE 12: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)

FIGURE 13: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)

FIGURE 14: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 15: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)

FIGURE 16: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)

FIGURE 17: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)

FIGURE 18: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)

FIGURE 19: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)

FIGURE 20: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)

FIGURE 21: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)

FIGURE 22: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)

FIGURE 23: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)

FIGURE 24: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)

FIGURE 25: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)

FIGURE 26: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)

FIGURE 27: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 28: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)

FIGURE 29: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)

FIGURE 30: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)

FIGURE 31: UNITED ARAB EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 32: SAUDI ARABIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 33: TURKEY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 34: SOUTH AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

FIGURE 35: REST OF MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

 

The growth of the biotechnology & pharmaceutical sectors primarily drive the market growth in the region

 

MARKET OUTLOOK

Triton Market Research’s study on the immunoglobulin market in the Middle East and Africa states that it is likely to show growth with a CAGR of 5.19% over the forecasting years 2022-2028. Saudi Arabia, Turkey, the United Arab Emirates, South Africa, and Rest of Middle East & Africa are evaluated in the market in this region.

In Saudi Arabia, the biotechnology and pharmaceutical industry’s growth and significant investments are boosting the immunoglobulin market. Also, the country is expected to grow substantially in the field of biotechnology, which is expected to drive its vaccine industry. For this, it invested $3.4 billion to achieve its goals towards pharmaceutical as well as health security in 2022. Further, the second phase of the investment is anticipated to focus on localizing immunological and cancer treatment technologies. Therefore, these initiatives are opening new avenues for the immunoglobulin market in this country.

An increasing number of product approvals and clinical trials were observed in the United Arab Emirates, which is expected to boost the demand for immunoglobulin. For instance, Sinopharm launched a COVID-19 drug clinical trial in 2021 after obtaining official authorization for the same. Moreover, the United Arab Emirates Ministry of Health and Prevention approved Sotrovimab, a human immunoglobulin G that can enable placental transfer from the mother to the fetus. Thus, all these developments across the country are likely to accelerate the growth of the immunoglobulin market.

 

Get more insights into the Middle East and Africa Immunoglobulin Market:

 

https://www.tritonmarketresearch.com/reports/middle-east-and-africa-immunoglobulin-market

 

COMPETITIVE OUTLOOK

Octapharma AG, ADMA Biologics, Bio Products Laboratory, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, Shanghai RAAS Blood Products Co Ltd, and Kamada Ltd are the key players in the immunoglobulin market.

 

SEGMENTATION

1.     BIOTEST AG

2.     CHINA BIOLOGIC PRODUCTS INC

3.     GRIFOLS SA

4.     LFB GROUP

5.     CSL BEHRING

6.     KEDRION BIOPHARMA

7.     OCTAPHARMA AG

8.     TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.     BIO PRODUCTS LABORATORY

10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD

11. PFIZER INC

12. SANQUIN PLASMA PRODUCTS BV

13. ADMA BIOLOGICS

14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD

15. KAMADA LTD